Breath-Based Monitoring of High Cholesterol State and Statin Therapy

Monitoring the effectiveness of statin therapy in patients with dyslipidemia is essential for ensuring optimal treatment outcomes. The current standard involves lipid profiling via blood tests to detect abnormalities in blood lipids. This study evaluated the feasibility of a non-invasive, breath-based approach to statin therapy monitoring using Noze’s electronic nose (eNose) platform. A total of 35 participants were enrolled, 25 with elevated low-density lipoprotein cholesterol (LDL-C) levels and 10 healthy controls. The high LDL-C group provided breath specimens both before starting statin therapy and after 6 to 8 weeks of treatment. These breath specimens were digitized using Noze’s eNose platform and analyzed using machine learning (ML) algorithms. Results showed a 91% sensitivity and 87% specificity in identifying high blood cholesterol cases, demonstrating the potential of Noze’s eNose platform for non-invasive monitoring of statin therapy through exhaled breath.